<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600028</url>
  </required_header>
  <id_info>
    <org_study_id>CG-0747</org_study_id>
    <secondary_id>CG-0747</secondary_id>
    <nct_id>NCT00600028</nct_id>
  </id_info>
  <brief_title>Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide</brief_title>
  <official_title>Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic Pulmonary Fibrosis (IPF) is a rapidly progressive lung disorder that is often
      associated with a chronic, intractable cough. The etiology of the cough associated with IPF
      is unclear but it is often so severe that it adversely effects the patient's quality of life.
      We propose that thalidomide specifically suppresses the cough associated with idiopathic
      pulmonary fibrosis via its anti-inflammatory properties, by suppressing the excessive
      functional up-regulation of sensory fibers with in the respiratory tract of patients with
      IPF.

      This study is a Phase III, double blinded, randomized, placebo controlled, crossover trial
      testing the efficacy of thalidomide in suppressing the chronic cough of IPF. The primary
      objective of this study is to determine the efficacy of thalidomide administered daily for 12
      weeks to suppress the chronic cough in patients with idiopathic pulmonary fibrosis as
      measured by cough specific questionnaires, scales and improved quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase III, double blinded, randomized, placebo controlled, crossover trial
      testing the efficacy of thalidomide in suppressing the chronic cough of IPF. All subjects
      will be randomized to either begin the study receiving the active study drug - (thalidomide)
      or inactive drug (placebo). Study drug will be administered in escalating dose starting at 50
      mg a day increasing to 100 mg a day if cough is still present after 2 weeks. Study drug will
      be taken by mouth at bedtime. Patients will remain on their initial treatment for 12 weeks.
      After 12 weeks of treatment, the subjects will be administered the Cough Specific Quality of
      Life Questionnaire (CQLQ), a visual cough analogue scale, and St. Georges Respiratory
      Questionnaire (SGRQ). In addition, investigators will collect the subjects cough diary. After
      12 weeks of treatment all subjects will enter a 2 week wash-out phase in which all drugs will
      be discontinued. After the 2 week wash-out phase, all subjects will again be administered the
      Cough Specific Quality of Life Questionnaire (CQLQ), a visual cough analogue scale, and St.
      Georges Respiratory Questionnaire (SGRQ). In addition, investigators will collect the
      subjects cough diary. All subjects will then be crossed over to the other treatment arm for
      an additional 12 weeks of treatment. After the second 12 weeks of treatment, the subjects
      will be administered the Cough Specific Quality of Life Questionnaire (CQLQ), a visual cough
      analogue scale, and St. Georges Respiratory Questionnaire (SGRQ). In addition, investigators
      will collect the subjects cough diary.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Thalidomide in Suppressing the Chronic Cough of Idiopathic Pulmonary Fibrosis Using the Cough Quality of Life Questionnaire.</measure>
    <time_frame>6 months</time_frame>
    <description>The primary endpoint, suppression of cough was measured by the Cough Quality of Life Questionnaire (CQLQ) to measure the effect of interventions on cough-specific quality of life.
CQLQ consist of 28 questions about cough and its effects using Likert-like 4-point scales, with lower scores indicating less effect of cough on health related quality of life.
CQLQ scale ranges from 28 to 112 ( The lower the value, the higher the quality of life, 28 is considered the best).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Thalidomide in Suppressing the Chronic Cough of Idiopathic Pulmonary Fibrosis Using the Visual Analog Scale of Cough and the St. George Respiratory Questionnaire.</measure>
    <time_frame>6 months</time_frame>
    <description>The secondary endpoint, suppression of cough was measured by the visual analog scale of cough (VAS) was significantly lower during treatment with thalidomide than placebo.
Secondary endpoints were Cough VAS - the visual analog scale of cough evaluates the severity of cough in patients with IPF.
Visual analog scale of cough ranges from 0 to 100 (0 is considered the best).
St. George Respiratory Questionnaire helps to evaluate cough-specific and respiratory quality of life in patients with IPF.
St. George Respiratory Questionnaire score ranges from 0 to 100 (0 is considered the best).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <condition>Cough</condition>
  <arm_group>
    <arm_group_label>Experimental: Thalidomide, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first received Thalidomide tablet for 12 weeks. After a washout period of two weeks, they then received placebo tablet for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Placebo, then Thalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first received Placebo tablet for 12 weeks. After a washout period of two weeks, they then received Thalidomide tablet for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Thalidomide 50 - 100 mg by mouth daily</description>
    <arm_group_label>Experimental: Thalidomide, then placebo</arm_group_label>
    <arm_group_label>Experimental: Placebo, then Thalidomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 50-100 mg by mouth per day</description>
    <arm_group_label>Experimental: Thalidomide, then placebo</arm_group_label>
    <arm_group_label>Experimental: Placebo, then Thalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic pulmonary fibrosis for &gt;3 months &lt;5 years

          -  High resolution CT scan of chest consistent with IPF within the previous 12 months

          -  FVC &gt; 40% and &lt; 90% predicted, TLC &gt;40% &lt;80%, DLCo &gt;30% &lt;90%

          -  Chronic Cough - cough &gt;8 weeks

          -  Age &gt;50

          -  Non-child bearing potential

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Women of child bearing potential

          -  Known etiology of lung fibrosis other than IPF

          -  Significant respiratory toxin exposure

          -  Collagen Vascular Disease

          -  Use of narcotic anti-cough agent in last week

          -  significant peripheral vascular disease or neuropathy

          -  history of seizures

          -  poorly controlled diabetes

          -  allergy to thalidomide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maureen Horton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2008</study_first_submitted>
  <study_first_submitted_qc>January 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2008</study_first_posted>
  <results_first_submitted>April 4, 2013</results_first_submitted>
  <results_first_submitted_qc>April 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 15, 2017</results_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Maureen R. Horton</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>idiopathic pulmonary fibrosis cough</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Cough</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Consecutive eligible patients were recruited by the investigators from their clinics and through self-referral between February 2008 and March 2011. 98 persons contacted our study coordinator with queries about the trial, 22 from the Johns Hopkins Interstitial Lung Disease Clinic and 76 in response to the ClinicalTrials.gov Web site.</recruitment_details>
      <pre_assignment_details>One participant was excluded because of an FVC&gt;90% predicted</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Drug Thalidomide First, Then Placebo</title>
          <description>Drug Thalidomide 50-100mg daily in the first intervention period and placebo daily in the second intervention period (after washout period)</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Thalidomide Drug</title>
          <description>Placebo was administered in the first interventional period and Thalidomide 50-100mg daily in the second interventional period (after washout period).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (12 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13">Number of participants starting the first intervention (prior to washout)</participants>
                <participants group_id="P2" count="11">Number of participants starting the first intervention (prior to washout)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (12 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12">Number of participants starting the second intervention (after a 2-week washout)</participants>
                <participants group_id="P2" count="10">Number of participants starting the second intervention (after a 2-week washout)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Drug Thalidomide First, Then Placebo</title>
          <description>Drug thalidomide 50 - 100 mg daily in the first intervention period and placebo daily in the second intervention period (after washout period)</description>
        </group>
        <group group_id="B2">
          <title>Placebo First, Then Thalidomide Drug</title>
          <description>Placebo was administered in the first intervention period and Thalidomide 50 - 100 mg daily in the second intervention period(After washout period)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.5" spread="7.11"/>
                    <measurement group_id="B2" value="65.55" spread="7.38"/>
                    <measurement group_id="B3" value="67.8" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Thalidomide in Suppressing the Chronic Cough of Idiopathic Pulmonary Fibrosis Using the Cough Quality of Life Questionnaire.</title>
        <description>The primary endpoint, suppression of cough was measured by the Cough Quality of Life Questionnaire (CQLQ) to measure the effect of interventions on cough-specific quality of life.
CQLQ consist of 28 questions about cough and its effects using Likert-like 4-point scales, with lower scores indicating less effect of cough on health related quality of life.
CQLQ scale ranges from 28 to 112 ( The lower the value, the higher the quality of life, 28 is considered the best).</description>
        <time_frame>6 months</time_frame>
        <population>All participants who received the interventions and completed all study visits were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm Thalidomide 1st, Placebo 2nd (Intervention Thalidomide)</title>
            <description>Intervention Thalidomide : thalidomide 50 - 100 mg by mouth daily in the first intervention period</description>
          </group>
          <group group_id="O2">
            <title>Arm Thalidomide 1st, Placebo 2nd (Intervention Placebo)</title>
            <description>Intervention Placebo : Placebo 50-100 mg by mouth per day in the second intervention period</description>
          </group>
          <group group_id="O3">
            <title>Arm Placebo 1st, Thalidomide 2nd (Intervention Placebo)</title>
            <description>Intervention Placebo : Placebo 50 - 100 mg by mouth daily in the first intervention period</description>
          </group>
          <group group_id="O4">
            <title>Arm Placebo 1st, Thalidomide 2nd (Intervention Thalidomide)</title>
            <description>Intervention Thalidomide : thalidomide 50 - 100 mg by mouth daily in the second intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Thalidomide in Suppressing the Chronic Cough of Idiopathic Pulmonary Fibrosis Using the Cough Quality of Life Questionnaire.</title>
          <description>The primary endpoint, suppression of cough was measured by the Cough Quality of Life Questionnaire (CQLQ) to measure the effect of interventions on cough-specific quality of life.
CQLQ consist of 28 questions about cough and its effects using Likert-like 4-point scales, with lower scores indicating less effect of cough on health related quality of life.
CQLQ scale ranges from 28 to 112 ( The lower the value, the higher the quality of life, 28 is considered the best).</description>
          <population>All participants who received the interventions and completed all study visits were included in the efficacy analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" spread="13.7"/>
                    <measurement group_id="O2" value="55.2" spread="14.4"/>
                    <measurement group_id="O3" value="61.6" spread="11.9"/>
                    <measurement group_id="O4" value="44.5" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The values represents three months on each intervention</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of Thalidomide in Suppressing the Chronic Cough of Idiopathic Pulmonary Fibrosis Using the Visual Analog Scale of Cough and the St. George Respiratory Questionnaire.</title>
        <description>The secondary endpoint, suppression of cough was measured by the visual analog scale of cough (VAS) was significantly lower during treatment with thalidomide than placebo.
Secondary endpoints were Cough VAS - the visual analog scale of cough evaluates the severity of cough in patients with IPF.
Visual analog scale of cough ranges from 0 to 100 (0 is considered the best).
St. George Respiratory Questionnaire helps to evaluate cough-specific and respiratory quality of life in patients with IPF.
St. George Respiratory Questionnaire score ranges from 0 to 100 (0 is considered the best).</description>
        <time_frame>6 months</time_frame>
        <population>All participants who received the interventions and completed all study visits were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm Thalidomide 1st, Placebo 2nd (Intervention Thalidomide)</title>
            <description>Intervention Thalidomide : thalidomide 50 - 100 mg by mouth daily in the first intervention period</description>
          </group>
          <group group_id="O2">
            <title>Arm Thalidomide 1st, Placebo 2nd (Intervention Placebo)</title>
            <description>Intervention Placebo : Placebo 50-100 mg by mouth per day in the second intervention period</description>
          </group>
          <group group_id="O3">
            <title>Arm Placebo 1st, Thalidomide 2nd (Intervention Placebo)</title>
            <description>Intervention Placebo : Placebo 50-100 mg by mouth per day in the first intervention period</description>
          </group>
          <group group_id="O4">
            <title>Arm Placebo 1st, Thalidomide 2nd (Intervention Thalidomide)</title>
            <description>Intervention Thalidomide : thalidomide 50 - 100 mg by mouth daily in the second intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Thalidomide in Suppressing the Chronic Cough of Idiopathic Pulmonary Fibrosis Using the Visual Analog Scale of Cough and the St. George Respiratory Questionnaire.</title>
          <description>The secondary endpoint, suppression of cough was measured by the visual analog scale of cough (VAS) was significantly lower during treatment with thalidomide than placebo.
Secondary endpoints were Cough VAS - the visual analog scale of cough evaluates the severity of cough in patients with IPF.
Visual analog scale of cough ranges from 0 to 100 (0 is considered the best).
St. George Respiratory Questionnaire helps to evaluate cough-specific and respiratory quality of life in patients with IPF.
St. George Respiratory Questionnaire score ranges from 0 to 100 (0 is considered the best).</description>
          <population>All participants who received the interventions and completed all study visits were included in the efficacy analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severity of cough (VAS Score)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" spread="28.5"/>
                    <measurement group_id="O2" value="65.9" spread="23.3"/>
                    <measurement group_id="O3" value="68" spread="26.8"/>
                    <measurement group_id="O4" value="17.8" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quality of life (SGRQ Score)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4" spread="19.4"/>
                    <measurement group_id="O2" value="54.7" spread="16.9"/>
                    <measurement group_id="O3" value="58.8" spread="13.3"/>
                    <measurement group_id="O4" value="40.7" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The values represents three months on each intervention</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Thalidomide</title>
          <description>Thalidomide : thalidomide 50 - 100 mg by mouth daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo : Placebo 50-100 mg by mouth per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maureen R. Horton</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-955-4176</phone>
      <email>mhorton2@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

